239 related articles for article (PubMed ID: 24822185)
21. Ascites-Derived Extracellular microRNAs as Potential Biomarkers for Ovarian Cancer.
Záveský L; Jandáková E; Weinberger V; Minář L; Hanzíková V; Dušková D; Drábková LZ; Svobodová I; Hořínek A
Reprod Sci; 2019 Apr; 26(4):510-522. PubMed ID: 29779470
[TBL] [Abstract][Full Text] [Related]
22. miRNA profile in ovarian cancer.
Ghafouri-Fard S; Shoorei H; Taheri M
Exp Mol Pathol; 2020 Apr; 113():104381. PubMed ID: 31954715
[TBL] [Abstract][Full Text] [Related]
23. Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis.
Loginov VI; Pronina IV; Burdennyy AM; Filippova EA; Kazubskaya TP; Kushlinsky DN; Utkin DO; Khodyrev DS; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2018 Jul; 662():28-36. PubMed ID: 29631007
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS.
Fu X; Cui Y; Yang S; Xu Y; Zhang Z
Tumour Biol; 2016 May; 37(5):6477-83. PubMed ID: 26631045
[TBL] [Abstract][Full Text] [Related]
25. The Significance of MicroRNAs Expression in Regulation of Extracellular Matrix and Other Drug Resistant Genes in Drug Resistant Ovarian Cancer Cell Lines.
Kazmierczak D; Jopek K; Sterzynska K; Ginter-Matuszewska B; Nowicki M; Rucinski M; Januchowski R
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283808
[TBL] [Abstract][Full Text] [Related]
26. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
Yang L; Li N; Wang H; Jia X; Wang X; Luo J
Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
[TBL] [Abstract][Full Text] [Related]
27. Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.
Zhang X; Guo G; Wang G; Zhao J; Wang B; Yu X; Ding Y
Mol Med Rep; 2015 Dec; 12(6):8021-31. PubMed ID: 26497752
[TBL] [Abstract][Full Text] [Related]
28. β-catenin downregulates Dicer to promote ovarian cancer metastasis.
To SKY; Mak ASC; Eva Fung YM; Che CM; Li SS; Deng W; Ru B; Zhang J; Wong AST
Oncogene; 2017 Oct; 36(43):5927-5938. PubMed ID: 28650464
[TBL] [Abstract][Full Text] [Related]
29. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer.
Hu X; Macdonald DM; Huettner PC; Feng Z; El Naqa IM; Schwarz JK; Mutch DG; Grigsby PW; Powell SN; Wang X
Gynecol Oncol; 2009 Sep; 114(3):457-64. PubMed ID: 19501389
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway.
Chen S; Chen X; Xiu YL; Sun KX; Zhao Y
PLoS One; 2015; 10(5):e0125714. PubMed ID: 25933027
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic Value of a Group of MicroRNA Genes Hypermethylated in Ovarian Carcinoma.
Braga EA; Loginov VI; Filippova EA; Burdennyi AM; Pronina IV; Kazubskaya TP; Khodyrev DS; Utkin DO; Kushlinskii DN; Adamyan LV; Kuslinskii NE
Bull Exp Biol Med; 2018 Dec; 166(2):253-256. PubMed ID: 30488208
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
33. miR-509-3p enhances platinum drug sensitivity in ovarian cancer.
Niu L; Ni H; Hou Y; Du Q; Li H
Gene; 2019 Feb; 686():63-67. PubMed ID: 30408550
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-296-5p Promotes Cell Invasion and Drug Resistance by Targeting Bcl2-Related Ovarian Killer, Leading to a Poor Prognosis in Pancreatic Cancer.
Okazaki J; Tanahashi T; Sato Y; Miyoshi J; Nakagawa T; Kimura T; Miyamoto H; Fujino Y; Nakamura F; Takehara M; Ma B; Bando M; Kitamura S; Okamoto K; Muguruma N; Sogabe M; Takayama T
Digestion; 2020; 101(6):794-806. PubMed ID: 31563901
[TBL] [Abstract][Full Text] [Related]
35. Clinical relevance of circulating cell-free microRNAs in ovarian cancer.
Nakamura K; Sawada K; Yoshimura A; Kinose Y; Nakatsuka E; Kimura T
Mol Cancer; 2016 Jun; 15(1):48. PubMed ID: 27343009
[TBL] [Abstract][Full Text] [Related]
36. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.
Yu X; Zhang X; Bi T; Ding Y; Zhao J; Wang C; Jia T; Han D; Guo G; Wang B; Jiang J; Cui S
Tumour Biol; 2013 Dec; 34(6):3501-8. PubMed ID: 23836287
[TBL] [Abstract][Full Text] [Related]
37. The Value of Plasma-Based MicroRNAs as Diagnostic Biomarkers for Ovarian Cancer.
Wang W; Yin Y; Shan X; Zhou X; Liu P; Cao Q; Zhu D; Zhang J; Zhu W
Am J Med Sci; 2019 Oct; 358(4):256-267. PubMed ID: 31353030
[TBL] [Abstract][Full Text] [Related]
38. Circulating and Tissue microRNAs as Biomarkers for Ovarian Cancer Prognosis.
Parizadeh SM; Jafarzadeh-Esfehani R; Ghandehari M; Hasanzadeh M; Parizadeh SMR; Hassanian SM; Rezaei-Kalat A; Aghabozorgi AS; Rahimi-Kakhki R; Zargaran B; Ferns GA; Avan A
Curr Drug Targets; 2019; 20(14):1447-1460. PubMed ID: 31284859
[TBL] [Abstract][Full Text] [Related]
39. Transcription factor-microRNA-target gene networks associated with ovarian cancer survival and recurrence.
Delfino KR; Rodriguez-Zas SL
PLoS One; 2013; 8(3):e58608. PubMed ID: 23554906
[TBL] [Abstract][Full Text] [Related]
40. [MicroRNA Analysis in Epithelial Ovarian Cancer].
Sommerová L; Ďuríková H; Podhorec J; Hrstka R
Klin Onkol; 2017; 30(Supplementum1):180-183. PubMed ID: 28471201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
